571 related articles for article (PubMed ID: 25715763)
1. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
[TBL] [Abstract][Full Text] [Related]
2. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.
Bendell JC; Hong DS; Burris HA; Naing A; Jones SF; Falchook G; Bricmont P; Elekes A; Rock EP; Kurzrock R
Cancer Chemother Pharmacol; 2014 Jul; 74(1):125-30. PubMed ID: 24819685
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.
Ogura M; Uchida T; Terui Y; Hayakawa F; Kobayashi Y; Taniwaki M; Takamatsu Y; Naoe T; Tobinai K; Munakata W; Yamauchi T; Kageyama A; Yuasa M; Motoyama M; Tsunoda T; Hatake K
Cancer Sci; 2015 Jul; 106(7):896-901. PubMed ID: 25912076
[TBL] [Abstract][Full Text] [Related]
4. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ
Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767
[TBL] [Abstract][Full Text] [Related]
6. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
7. A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Tolcher A; Flaherty K; Shapiro GI; Berlin J; Witzig T; Habermann T; Bullock A; Rock E; Elekes A; Lin C; Kostic D; Ohi N; Rasco D; Papadopoulos KP; Patnaik A; Smith L; Cote GM
Oncologist; 2018 Jun; 23(6):658-e72. PubMed ID: 29511132
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors.
Kawazoe A; Kuboki Y; Bando H; Fukuoka S; Kojima T; Naito Y; Iino S; Yodo Y; Doi T; Shitara K; Yoshino T
Cancer Chemother Pharmacol; 2020 May; 85(5):855-862. PubMed ID: 32236642
[TBL] [Abstract][Full Text] [Related]
9. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.
Fu S; Hirte H; Welch S; Ilenchuk TT; Lutes T; Rice C; Fields N; Nemet A; Dugourd D; Piha-Paul S; Subbiah V; Liu L; Gong J; Hong D; Stewart JM
Invest New Drugs; 2017 Jun; 35(3):324-333. PubMed ID: 28150073
[TBL] [Abstract][Full Text] [Related]
11. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
14. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.
Yoo C; Kang J; Lim HY; Kim JH; Lee MA; Lee KH; Kim TY; Ryoo BY
Cancer Res Treat; 2019 Apr; 51(2):510-518. PubMed ID: 29898591
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
[TBL] [Abstract][Full Text] [Related]
16. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
17. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
18. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
